RudaCure, which is developing pain treatments, has today completed the patent filing for its invention of peptides with TRPV1 inhibitory activity.
Combined with AI-based drug screening and traditional in vitro and in vivo methods, RudaCure has secured a group of active peptides. This is a substance patent and use patent filing for materials that demonstrate efficacy and side effect suppression in various pain animal models.
Negotiations are underway with a domestic company for joint research on these materials, and discussions are also in progress with multinational pharmaceutical companies. These compounds are expected to emerge as a new option in the pain market, where there is high demand for non-addictive, side-effect-free drugs.
